Jazz Pharmaceuticals to acquire Redx’s KRAS inhibitorKRAS inhibitor programme
引进/卖出
Preview
来源: Pharmaceutical Technology
The companies will partner to advance KRAS inhibitorKRAS inhibitor candidates through IND-enabling studies. Credit: Alexander Raths / Shutterstock.com.
Jazz Pharmaceuticals has entered a definitive agreement for the acquisition of the worldwide rights for a Kirsten rat sarcoma virus (KRAS) inhibitor programme from Redx Pharma in an $880m deal.
Jazz will gain access to the programme’s rights, patents and interests and will make an upfront payment of $10m to Redx.
Redx is entitled to receive milestone payments of $870m from Jazz on meeting development, regulatory and commercial goals.
The next milestone is the investigational new drug application (IND) clearance from the US Food and Drug Administration.
Redx will also earn royalties on net product sales, expected to be in the mid-single digit percentage range.
See Also:LP-410 by Lipella Pharmaceuticals for Graft Versus Host Disease (GVHD): Likelihood of Approval
Preview
来源: Pharmaceutical Technology
Undisclosed 1 by Palleon Pharmaceuticals for Autoimmune Disorders: Likelihood of Approval
Preview
来源: Pharmaceutical Technology
The companies will partner to advance the KRAS inhibitorKRAS inhibitor candidates through IND-enabling studies.
Jazz will subsequently oversee their clinical development, regulatory processes, production and marketing.
The candidates include molecules selective for G12D mutations and pan-KRAS inhibitors.
Jazz will also compensate Redx for conducting research and preclinical development activities.
Jazz Pharmaceuticals research and development global head and executive vice-president Robert Iannone stated: “KRAS is a well-validated oncology target and there remains a high unmet need for innovation in this area based on challenges in developing molecules to target specific KRAS mutations.
“This transaction further expands our early-stage oncology pipeline, and we are excited to explore novel approaches to improving treatment options for cancer patients.”
The latest development comes after Jazz and the University of Texas MD Anderson Cancer CenterCancer Center signed a research partnership to evaluate the former’s zanidatamab for HER2-expressing cancersHER2-expressing cancers.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。